Nasus Pharma Ltd.

Virtual Investor Conferences announced that presentations from the June 24-25 Life Sciences Virtual Investor Forum are now available for on-demand viewing for 90 days. Twenty companies across the life sciences sector presented at the forum, with select companies still accepting 1x1 management meeting requests through June 19th.

Nasus Pharma reported positive Phase 2 results for NS002, its intranasal epinephrine powder, demonstrating statistically significant improvements in absorption speed compared to EpiPen®. The company plans to initiate a pivotal study in Q4 2026 and is advancing pipeline candidates NS003, NS004, and NS005 toward first-in-human studies in H2 2026. ...

Nasus Pharma Ltd. (NYSE: NSRX), a clinical-stage pharmaceutical company developing intranasal products, announced that CEO Dan Teleman will present at three upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 25), BIO Investment & Growth Summit (Mar 2), and Citizens Life Sciences Conference (Mar 3). The...

Nasus Pharma Ltd. (NYSE: NSRX) announced the closing of a private placement raising approximately $15.0 million gross proceeds through the sale of 2,695,425 ordinary shares and accompanying warrants at $5.565 per share. The company plans to use the proceeds to advance its NS002 intranasal epinephrine powder product candidate toward a pivotal stud...

Nasus Pharma Ltd. (NYSE: NSRX), a clinical-stage pharmaceutical company, announced a private placement of 2.7 million ordinary shares and warrants for approximately $15 million in gross proceeds. The funds will be used to advance pivotal clinical development of NS002, an intranasal epinephrine product for anaphylaxis treatment, and to initiate fi...